A newly published study in Nature Medicine offers a fresh angle on one of the most debated questions in neurology: what actually sets off a multiple sclerosis relapse? According to the paper, published online on 16 September 2026, increased expression of Epstein-Barr virus (EBV) reactivation genes in B cells — together with MS risk genes targeted by the EBV protein EBNA-2 — precedes relapse, suggesting the peripheral immune system is being primed before symptoms flare.
The findings do not settle the long-running question of whether EBV causes MS. But they add something that has often been missing from the debate: a sense of sequence and timing. Rather than treating EBV as a distant risk factor operating years before disease onset, the new work points to measurable viral activity inside the immune system in the period leading up to a relapse.
What the Study Reports
At the center of the paper are two connected observations. First, B cells showed increased expression of genes associated with EBV reactivation — the process by which the virus, which normally sits dormant inside cells, begins producing viral products again. Second, genes known to be associated with MS risk, and specifically those targeted by the viral protein EBNA-2, showed increased expression in the same window.
Critically, these changes appear to come before relapse rather than simply accompanying it. That ordering matters. It hints at a mechanism in which viral reactivation helps set the stage for inflammation in the central nervous system, rather than being a bystander effect of immune activation that is already underway.
- Increased expression of EBV reactivation genes in B cells in the run-up to relapse.
- Increased expression of MS risk genes that are targets of the EBV protein EBNA-2.
- A temporal pattern in which these signals precede, rather than follow, clinical relapse.
Why B Cells and EBV Have Long Been Suspects
EBV is a herpesvirus that establishes lifelong latency in the body, with B cells serving as a major reservoir. Its association with MS has been studied for years, and interest intensified as epidemiological and immunological evidence accumulated linking EBV infection to the development of the disease. Yet association is not mechanism, and the field has long lacked a clear picture of how a common virus might translate into a relapsing neurological condition in only some people.
The B cell connection has always been central to that puzzle. B cells are both a home for latent EBV and a key player in the immune response that damages myelin in MS. Therapies that deplete B cells are among the most effective treatments for the disease, which has reinforced the idea that whatever EBV is doing, it is likely doing it through, or at least alongside, B cell biology.
EBNA-2 as a Molecular Lever
EBNA-2 is one of the viral proteins that allows EBV to reprogram the cells it infects. It acts as a regulator of gene expression, influencing how host genes are switched on or off. The new study's emphasis on MS risk genes that are targeted by EBNA-2 is significant because it offers a plausible molecular bridge: a viral protein reaching into human gene regulation and touching the very genes that genetic studies have already flagged as relevant to MS risk.
In other words, the paper does not simply note that the virus and the disease appear together. It proposes a specific route by which viral activity could interact with inherited susceptibility — a route that shows up in B cells ahead of a relapse.
A Timeline Rather Than a Correlation
Much of the existing evidence around EBV and MS describes a relationship that plays out over years — infection earlier in life, followed much later by neurological disease. The new findings operate on a far shorter timescale: the period immediately preceding a relapse.
If the pattern holds, it would reframe EBV's role from background risk factor to active participant in flares. That has practical consequences. A virus that is reactivating in a measurable way before relapse is, in principle, something that could be monitored — and perhaps eventually interrupted.
What It Could Mean for Treatment and Monitoring
The study does not report a new therapy, and no clinical recommendations follow directly from it. But it sketches a research direction with several strands.
- Monitoring: if EBV reactivation markers rise before relapse, they could conceivably form part of a biomarker panel for anticipating flares.
- Intervention: antiviral or EBV-directed strategies would move up the list of approaches worth testing if reactivation turns out to be causally involved.
- Existing therapies: the findings fit with the established effectiveness of B cell–depleting treatments and may help explain part of why they work.
Each of these remains speculative for now. Turning a temporal association into a treatment target requires controlled trials, not just observations.
The Questions That Remain Open
Several important caveats temper the results. The most fundamental is causality. Signals that precede relapse are consistent with a trigger, but they are also consistent with an early, subclinical phase of the same immune process that ultimately produces symptoms. Distinguishing those possibilities will require careful longitudinal work in which patients are followed closely enough to see whether viral activity reliably comes first.
- Does EBV reactivation drive relapse, or does an emerging relapse create conditions that allow the virus to reactivate?
- How consistent is the pattern across patients, disease subtypes, and treatment histories?
- Can blocking reactivation actually reduce relapse frequency, or would it make no measurable difference?
There is also the question of generalizability. MS is a heterogeneous disease, and findings drawn from one group of patients do not automatically describe every person living with the condition. Replication in independent cohorts will be an important next step.
The Bigger Picture
What makes this paper notable is less any single measurement than the convergence it represents. Genetic studies point to specific risk genes. Immunology points to B cells. Virology points to EBV and, specifically, to the EBNA-2 protein. The new work places all three on the same timeline ahead of relapse, producing a picture in which viral reactivation, host gene activity, and B cell biology line up in a sequence rather than sitting in separate compartments of the literature.
For people living with MS, the practical takeaway today is limited. This is a research finding, not a change in care, and its immediate value lies in the hypotheses it generates. Still, it strengthens a line of inquiry that could eventually yield ways to predict flares or interrupt them before they begin.
If EBV reactivation is part of the priming process, then the long-running question of what sets off a relapse may have at least part of its answer hiding in a virus that most people carry without ever knowing it — and which, in this study, appears to make itself known in the immune system just before the disease does.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
